Aberrant immunomodulatory signature in β-propeller protein-associated neurodegeneration patient iPSC-derived

Gamze Özata1,2, Rachel M Wise1, Aida Cardona-Alberich1

  • 1Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, Germany.

Scientific Reports
|June 15, 2026
PubMed

Insights

Microglia, the brain's immune cells, show a distinct stress-adapted phenotype in BPAN (β-propeller protein-associated neurodegeneration). This dysfunction suggests novel therapeutic targets for this rare neurodegenerative disease.

Area of Science:

  • Neuroimmunology
  • Neurodegenerative Diseases
  • Cellular Biology

Background:

  • Microglia are crucial for brain homeostasis and implicated in neurodegenerative diseases like Parkinson's.
  • The role of microglia in rare neurodegenerative disorders, such as BPAN, is largely unknown.
  • BPAN shares features with Parkinson's, including iron accumulation and dopaminergic neuron loss.

Purpose of the Study:

  • To investigate the impact of microglia and WDR45 mutations in BPAN pathophysiology.
  • To establish and characterize the first induced pluripotent stem cell (iPSC)-derived microglia model from BPAN patients.

Main Methods:

  • Generation of iPSC-derived microglia from BPAN patients.
  • Targeted transcriptomic and secretomic profiling of BPAN microglia.
  • Analysis of immune signaling, autophagy, and cellular stress responses.

Main Results:

  • BPAN microglia exhibit a stress-adapted, transcriptionally reprogrammed state distinct from homeostatic microglia.
  • Dysregulation of immune signaling pathways, autophagy, and cellular stress responses were observed.
  • Reduced lysosomal enzyme secretion and increased shedding of immune-associated surface proteins indicate altered lysosomal trafficking and immune signaling.

Conclusions:

  • A distinct microglial phenotype is identified in BPAN.
  • Microglial dysfunction is implicated as a potential contributor to BPAN pathogenesis.
  • These findings highlight neuroimmune pathways as potential therapeutic targets for BPAN.